AbbVie (ABBV) Gets $260 Price Target Upgrades Amid Growing Valuation Worries

Key Takeaways

• 32 Wall Street firms give AbbVie an average brokerage score of 1.61 (positioned between Strong Buy and Buy), including 21 Strong Buy recommendations
• Citi and UBS both increased ABBV price targets from $230 to $260
• Both investment banks keep Neutral ratings despite higher price objectives
• Zacks assigns ABBV a Rank #4 (Sell), noting consensus EPS projections for the year declined 0.6% to $14.23
• GuruFocus indicates ABBV trades approximately 16.4% above fair value, with a P/E ratio of 121.77x compared to its 5-year median of 47.36x

AbbVie (ABBV) has captured Wall Street’s focus this week as two prominent investment banks increased their price objectives — though neither is urging investors to rush in.

AbbVie Inc., ABBV

Shares of ABBV were changing hands near $247.19 according to recent data, with Citi and UBS establishing fresh $260 targets, elevated from their previous $230 marks. This represents a 13% increase in projected valuation. However, both institutions retained Neutral ratings, suggesting a measured approach rather than enthusiastic endorsement.

Citi’s analyst Geoff Meacham adjusted the target while conducting a comprehensive Q2 earnings assessment for the biopharmaceutical sector. The bank anticipates “largely robust” second-quarter performance from major pharmaceutical companies under its coverage. UBS analyst Michael Yee mirrored this tempered optimism — raising expectations while maintaining a neutral position.

The conflicting indicators continue.

AbbVie’s average brokerage recommendation (ABR) from 32 institutions registers at 1.61 — positioned between Strong Buy and Buy categories.

Among these 32 assessments, 21 carry Strong Buy designations and two are rated Buy. Superficially, this appears encouraging.

Yet Zacks presents an alternative perspective.

Zacks Issues Sell Recommendation for ABBV

AbbVie currently holds a Zacks Rank of #4 (Sell). The Zacks Consensus Estimate for annual EPS has decreased 0.6% during the previous month, landing at $14.23. Analysts have been gradually adjusting their earnings projections downward, a pattern that carries significant weight in Zacks’ methodology.

Zacks emphasizes that brokerage recommendations — despite their popularity — frequently exhibit positive bias stemming from commercial relationships between firms and covered companies. Their research reveals analysts distribute approximately five Strong Buy ratings for each Strong Sell recommendation. Consequently, that 1.61 ABR might not represent the clear signal it initially suggests.

The valuation analysis introduces additional complexity. GuruFocus calculates AbbVie’s GF Value at $212.31, positioning the current trading price approximately 16.4% beyond their calculated fair value. The stock’s trailing P/E stands at 121.77x — exceeding its five-year median of 47.36x by more than double.

Performance Metrics and Insider Transactions

GuruFocus assigns ABBV a GF Score of 81 out of 100, indicating strong overall performance metrics. Profitability receives an 8/10 rating and growth scores 7/10. Financial strength, however, registers only 4/10 — a metric that warrants attention.

Regarding insider activity, no purchases or sales have been documented over the recent three-month period. Company insiders remain inactive.

AbbVie’s Q2 earnings announcement approaches, with Citi’s analysis suggesting potentially strong results. The stock has gained approximately 1% during today’s trading session.

The post AbbVie (ABBV) Gets $260 Price Target Upgrades Amid Growing Valuation Worries appeared first on Blockonomi.